Tucatinib 150mg PHOTUCA 150

The following is the general instructions for Tucatinib, which is for reference only. Please refer to the instructions in the drug packaging for specific use and follow the doctor's instructions.

---

Drug Name

Generic Name: Tucatinib
Product name: PHOTUCA 150

---

Indications

Tucatinib is a targeted drug used to treat the following diseases:

1. HER2-positive breast cancer :
   • It is used to treat HER2-positive advanced or metastatic breast cancer, especially in patients whose disease has progressed after other treatments such as chemotherapy and HER2-targeted drugs.
   • Tucatinib is usually used in combination with other anticancer drugs (such as capecitabine) and is suitable for patients who have received at least two lines of treatment.

---

Mechanism of action

Tucatinib is an oral selective HER2 tyrosine kinase inhibitor that can specifically inhibit the tyrosine kinase activity of the HER2 receptor, block HER2-mediated signal transduction, and thus inhibit the proliferation and growth of cancer cells. Its targeting makes it highly selective and effective against HER2-positive tumor cells.

---

Dosage

• Recommended dose :
  • The standard dose of tucatinib is 300 mg orally twice daily.
• Directions :
  • Can be taken with or without food.
  • Tablets should be swallowed whole and should not be crushed, chewed or split.
• Dosage adjustments :
  • If serious adverse reactions occur, your doctor may suspend treatment or adjust the dosage.
  • For patients with impaired liver function, the dose may need to be adjusted on a case-by-case basis.

---

Precautions

1. Side Effect Monitoring :
   • Common side effects : diarrhea, fatigue, loss of appetite, nausea, vomiting, rash, mouth ulcers, etc.
   • Serious side effects : severe diarrhea (may cause dehydration), abnormal liver function (including increased ALT and AST), severe skin reactions, etc.
2. Use in special populations :
   • Pregnant and lactating women : Contraindicated, tucatinib may cause harm to the fetus or infant.
   • Children : Safety and effectiveness have not been established and it is generally not recommended for use in children under 18 years of age.
   • Elderly : Elderly patients may have poorer tolerance to medications and should use the drug with caution depending on their overall health status.
3. Other notes :
   • During treatment, especially in the early stages of treatment, liver function, diarrhea and skin reactions need to be closely monitored.
   • If severe diarrhea or abnormal liver function occurs, seek medical attention promptly and adjust the treatment plan.

---

Drug interactions

• CYP3A4 inhibitors : such as ketoconazole and erythromycin, may increase the blood concentration of tucatinib and should be used with caution.
• CYP3A4 inducers : such as rifampicin and St. John's wort, may reduce the efficacy of tucatinib and should be avoided in combination.
• Other drugs : When used in combination with other drugs, special attention should be paid to drug interactions, especially drugs that affect liver metabolism.

---

Contraindications

• Patients who are allergic to tucatinib or its excipients are contraindicated.
• It is contraindicated for pregnant and lactating women.

---

Storage conditions

• Store in a dry environment at 20°C to 25°C.
• Avoid high temperature, humidity and direct light, and the medicine should be stored out of the reach of children.

---

Important Tips

• Treatment with tucatinib should be performed under the guidance of a physician with relevant cancer treatment experience.
• Regularly check liver function, diarrhea, and skin reactions.
• If serious adverse reactions occur (such as severe diarrhea, abnormal liver function or skin lesions), treatment should be suspended and medical attention should be sought promptly.

---

Note : If you need more detailed information or special case medication plans, please consult your doctor or pharmacist. If you have any other questions, please let me know!